Commentary Open Access
Volume 2 | Issue 1 | DOI: https://doi.org/10.46439/immunol.2.013
Immune checkpoint inhibitor therapy-associated myocarditis – Toward identification of an immune signature that can improve diagnosis
Pourya Yarahmadi1,2, Patricia Nguyen1,2,*
- 1Department of Medicine, Division of Cardiovascular Medicine, Stanford University, Stanford, CA, USA
- 2Stanford Cardiovascular Institute, Stanford, CA, USA
Corresponding Author
Patricia Nguyen, pknguyen@stanford.edu
Received Date: January 23, 2023
Accepted Date: February 06, 2023
Yarahmadi P, Nguyen P. Immune checkpoint inhibitor therapyassociated myocarditis – Toward identification of an immune signature that can improve diagnosis. J Cell Mol Immunol. 2023;2(1):6-8.
Copyright: © 2023 Yarahmadi P, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Recommended Articles
Immune checkpoint inhibitor therapy-associated myocarditis – Toward identification of an immune signature that can improve diagnosis
Immune checkpoint inhibitors (ICI) have emerged as promising treatment options for many cancers. ICIs exert their therapeutic effects by targeting immune inhibitory molecules on T-cells in adaptive immunity, such as cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), programmed cell death 1 (PD-1) and its ligand programmed cell death ligand 1 (PD-L1). ICIs, however, can result in a wide variety of immune-related adverse events (iRAE), including myocarditis, a rare and potentially deadly complication that necessitates early diagnosis.